Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07840677 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer

Study acronym: TRIUNITE-08
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study First Submitted
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally advanced colon adenocarcinoma .
Trial Details
NCT Number NCT07840677
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Collaborators: Shapingba District People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Jiangbei Campus of The First Affiliated Hospital of Army Medical University (Army 958 Hospital), Third Affiliated Hospital of Chongqing Medical University, Chongqing Yongchuan District People's Hospital, Deyang People's Hospital, Guang'an People's Hospital, Kaizhou District People's Hospital, 940 Hospital of the People's Liberation Army Joint Logistic Support Force
Conditions
(from sponsor)
Colon Cancer, PCSK9 Inhibitor, Neoadjuvant Immunochemotherapy
Related terms Colonic Neoplasms
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov